Glycosidases are involved in a broad range of biological and pathological processes. The development of inhibitors of these enzymes that could potentially help with diseases such as type II diabetes mellitus, viral infections, cancer or hereditary enzyme deficiency diseases is one of the aims of Jose M Garcia Fernandez, Carmen Ortiz Mellet and their research groups in Spain.
In this paper, they prepare a library of sp2-iminosugar-type glycomimetics and they evaluate their glycosidase inhibition properties against a panel of commercial glycosidases. They actually got very interesting results that show the potential of this molecular diversity-oriented approach to identify suitable hits for further in cell and in vivo studies.
Read this HOT article now that is free to access until the 5th May.
Bicyclic (galacto)nojirimycin analogues as glycosidase inhibitors: Effect of structural modifications in their pharmacological chaperone potential towards β-glucocerebrosidase
Matilde Aguilar-Moncayo, M. Isabel García-Moreno, Ana Trapero, Meritxell Egido-Gabás, Amadeu Llebaria, José M. García Fernández and Carmen Ortiz Mellet
Org. Biomol. Chem., 2011, Advance Article
DOI: 10.1039/C1OB05234A
